Anatara Lifesciences Ltd (AU:ANR) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Anatara Lifesciences Ltd has achieved positive momentum in its Stage 2 clinical trial for the GaRP-IBS treatment, with 36 participants already enrolled and more in the final screening phase. The company has expanded recruitment efforts by adding trial sites in Adelaide and Queensland, with strong community interest and active participation. Though the timeline for results has been extended, the completion of recruitment is expected by Q4 CY2024, with headline results anticipated in Q1 CY2025.
For further insights into AU:ANR stock, check out TipRanks’ Stock Analysis page.